Home
About
Overview
Sharing Data
ORCID
Help
History (15)
MET molecular mechanisms and therapies in lung cancer.
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells.
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer.
Clinical Utility of a Circulating Tumor Cell-Based Cerebrospinal Fluid Assay in the Diagnosis and Molecular Analysis of Leptomeningeal Disease in Patients With Advanced Non-Small Cell Lung Cancer.
HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression.
See All 15 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression.
HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression. Front Oncol. 2015; 5:164.
View in:
PubMed
authors with profiles
Ravi Salgia